NLS Pharmaceutics Says Preclinical Data Demonstrate The Potential Of Its Dual Orexin Receptor Agonist Platform, An Investigational New Drug Application Is Planned For 2026-2027
NLS Pharmaceutics Says Preclinical Data Demonstrate The Potential Of Its Dual Orexin Receptor Agonist Platform, An Investigational New Drug Application Is Planned For 2026-2027
NLS Pharmaceutics表示，臨床前數據顯示其雙血清素受體激動劑平台的潛力，計劃在2026-2027年提交研究新藥申請。
AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to target both orexin-1 (OX1R) and orexin-2 (OX2R) receptors while concurrently inhibiting cathepsins. Cathepsins play significant roles in a variety of physiological processes and may offer a novel therapeutic approach for narcolepsy and other neurological disorders.
AEX-41和AEX-2是兩種首創的非磺酰胺類DOXA，旨在同時靶向血清素-1（OX1R）和血清素-2（OX2R）受體，同時抑制貓細胞酶。貓細胞酶在多種生理過程中發揮重要作用，可能爲嗜睡症和其他神經系統疾病提供一種新的治療方法。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間